AbCellera Investor Conference Presentation Deck
CORPORATE OVERVIEW
COPYRIGHT © ABCELLERA
14
COVID-19 PROGRAM
VALIDATED THE
PLATFORM & CAPITAL
TO COMPLETE THE
STACK
AbCellera co-developed two
antibody treatments authorized
by the U.S. FDA to treat COVID-19.
bamlanivimab
U.S. FDA Authorization: November 2020
At the start of the COVID-19 pandemic in March 2020, AbCellera made a conscious
decision to first prioritize speed in getting therapies out to patients. This resulted in
the discovery of bamlanivimab, the first COVID-19 antibody to reach the clinic and to
receive Emergency Use Authorization by the FDA. Bamlanivimab, alone and with
other antibodies, has treated an estimated 1 million patients, preventing COVID-19-
related hospitalizations and death.
bebtelovimab
U.S. FDA Authorization: February 2022
AbCellera anticipated resistant strains would emerge and continued our screening
efforts to build a collection of several thousand diverse candidate antibodies. In
early 2021, responding to the emergence of new variants, we began to search this
library to find a next-generation solution, this time prioritizing maximum possible
potency and breadth of neutralization. This effort resulted in the discovery and the
Emergency Use Authorization of bebtelovimab. In addition to neutralizing every
known variant of concern, bebtelovimab is believed to be the most potent antibody
in development against the Omicron variant and the BA.2 subvariant.View entire presentation